SCHEDULE 13G 0001738048 XXXXXXXX LIVE Common Stock, $0.0001 par value per share 09/18/2025 0001817229 Vor Biopharma Inc. 929033207 500 Boylston Street Suite 1350 Boston MA 02116 Rule 13d-1(c) Venrock Healthcare Capital Partners III, L.P. a DE 0.00 760699.00 0.00 760699.00 760699.00 9.9 PN VHCP Co-Investment Holdings III, LLC a DE 0.00 760699.00 0.00 760699.00 760699.00 9.9 OO Venrock Healthcare Capital Partners EG, L.P. a DE 0.00 760699.00 0.00 760699.00 760699.00 9.9 PN VHCP Management III, LLC a DE 0.00 760699.00 0.00 760699.00 760699.00 9.9 OO VHCP Management EG, LLC a DE 0.00 760699.00 0.00 760699.00 760699.00 9.9 OO Nimish Shah a X1 0.00 760699.00 0.00 760699.00 760699.00 9.9 IN Bong Y. Koh a X1 0.00 760699.00 0.00 760699.00 760699.00 9.9 IN Vor Biopharma Inc. 500 Boylston Street, Suite 1350, Boston, MA, 02116. The names of the persons filing this report (collectively, the "Reporting Persons") are: Venrock Healthcare Capital Partners III, L.P. ("VHCP III") VHCP Co-Investment Holdings III, LLC ("VHCP Co-Investment III") Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG") VHCP Management III, LLC ("VHCP Management III") VHCP Management EG, LLC ("VHCP Management EG") Nimish Shah ("Shah") Bong Koh ("Koh") The Reporting Persons are members of a group for the purposes of this Schedule 13G. New York Office: 7 Bryant Park, 23rd Floor New York, NY 10018 Palo Alto Office: 3340 Hillview Avenue Palo Alto, CA 94304 All of the entities were organized in Delaware. Shah and Koh are both United States citizens. Y Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 116,542 shares of the Issuer's common stock and pre-funded warrants (the "Pre-Funded Warrants") exercisable for up to 1,048,950 shares of common stock held by VHCP III; (ii) 11,649 shares of the Issuer's common stock and Pre-Funded Warrants exercisable for up to 104,850 shares of common stock held by VHCP Co-Investment III; and (iii) 371,775 shares of the Issuer's common stock and Pre-Funded Warrants exercisable for up to 3,346,200 shares of common stock held by VHCP EG. The Pre-Funded Warrants contain a provision (the "Beneficial Ownership Blocker"), which precludes the exercise of the Pre-Funded Warrants to the extent that, following exercise, VHCP III, VHCP Co-Investment III and VHCP EG, together with their affiliates and other attribution parties, would own more than 9.99% of the outstanding shares of common stock. VHCP III, VHCP Co-Investment III and VHCP EG are currently prohibited from exercising the Pre-Funded Warrants to the extent that such exercise would result in beneficial ownership of more than 760,699 shares of common stock. VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG. Due to the Beneficial Ownership Blocker listed in the Pre-Funded Warrants, each Reporting Person's beneficial ownership percentage is 9.99%. Such percentage is based upon the sum of (i) 6,853,907 shares of common stock outstanding as of September 18, 2025, as reported in the Issuer's Registration Statement on Form S-3 filed with the Securities and Exchange Commission (the "SEC") on September 24, 2025; (ii) 499,966 shares of common stock issued subsequent to September 18, 2025 upon the exercise of Pre-Funded Warrants by the Reporting Persons; and (iii) 260,733 shares of common stock issuable upon the exercise of the Pre-Funded Warrants. Due to field limitations of the EDGAR filing system, the percentage listed in Row 11 of each Reporting Person's cover page has been rounded down to 9.9%. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 24.1 Power of Attorney for Bong Koh Exhibit 24.2 Power of Attorney for Nimish Shah Exhibit 99.1 Joint Filing Agreement Venrock Healthcare Capital Partners III, L.P. /s/ Sherman G. Souther 09/25/2025 VHCP Co-Investment Holdings III, LLC /s/ Sherman G. Souther 09/25/2025 Venrock Healthcare Capital Partners EG, L.P. /s/ Sherman G. Souther 09/25/2025 VHCP Management III, LLC /s/ Sherman G. Souther 09/25/2025 VHCP Management EG, LLC /s/ Sherman G. Souther 09/25/2025 Nimish Shah /s/ Sherman G. Souther 09/25/2025 Bong Y. Koh /s/ Sherman G. Souther 09/25/2025